Follow us on Facebook  Follow us on Twitter  Investors Hub Board
Wall Street Newscast  Where Wall Street Listens

Join Our Email List
Email:  

Home | Email Alerts | Message Board | Twitter | Awareness Services | Contact
stock picks



PuraMed BioScience, Inc (OTC:PMBS)
1326 Schofield Avenue
Schofield, WI 54476
Phone: 715-359-6373
Email: info@southstreetmedia.com 
Real-Time Quote

PMBS Mailing List

PMBS Message Board


Russ Mitchell, the CEO of PMBS Discusses Patent Portfolio Acquisition
(May 29, 2013)


About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. For more information visit www.puramedbioscience.com


Shares Authorized: 1 billion Public Float: UR
Shares Outstanding: 68 million Price Target: $0.04+

*
based on OTC Markets data


PMBS Confirms Market Cap only $210,000
Last Updated:
Nov. 24, 2013 - 2:00pm EST

(NEW YORK)--PuraMed BioScience, Inc. (OTC:PMBS), and developer of over-the-counter health and wellness products, confirms current shares outstanding and market cap of only $210,000.

The Company has confirmed that as of Nov. 24, 2013 there was approximately 68 million common shares issued and outstanding, and with a current price of $0.003 that is a market cap of only $210,000.

PMBS Highlights 

- To Acquire Disinfectant Product for China Distribution
- Shown Effective Against H7N9 Avian Flu Virus
- Product Shown Effective for Migraine Headaches
- Currently on Shelves at CVS and Walgreen's
- Planning Expansion to Walmart and Target
- 68 Million Shares Outstanding
- Market Cap well below $600,000

Disinfectant Product Deal for China

The Company has been progressing in its closure of its patent portfolio, and with special focus on an disinfectant product that would be marketed and distributed in China. This could be a major catalyst to jump start PMBS current market cap valuation as any distribution of an anti-viral or disinfectant product in China could have a tremendous upside potential to revenue generation.

With news of a new strain of the avian influenza in China, the H7N9 virus, the use of disinfectants for such areas of trains, hospitals, and other public areas could provide PMBS with a much needed kick start to investor interest. Initial tests with this new disinfectant product has already been shown effective against both the new H7N9, and other strains of influenza viruses. Talks on final closure of deal is progressing rapidly, and could have final terms to an agreement in the coming week or two.

In addition, as of Oct. 17, 2013, the Company stock was slapped with an "E", but this should be removed shortly as the company has now filed their 10K annual report, and is now compliant as fully reporting under the Securities Exchange Act of 1934.

Effective Treatment for Migraine Headaches

In a double-blind, placebo-controlled clinical trial for LipiGesic M, completed in 2010 and published in the July 2011 issue of Headache: The Journal of Head and Face Pain, concluded that 64 percent of patients who used LipiGesic M found relief. These results were featured in the February 2013 issue of
Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society.

Product on Shelves of Major Retail Stores

Unlike other developmental companies, PMBS's LipiGesic M product is already available over-the-counter at such major retail box chain stores as Walgreens and CVS Pharmacy's. The Company is currently ramping up plans to expand their retail distribution to other named stores such as Target and Safeway, and is expanding Internationally into South America as well.

PMBS Valuation and Price Target

As of Oct. 16, 2013, the Company had around 57 million shares issued and outstanding, thus giving PMBS a market capitalization well under a $1 million. Giving fact their over-the-counter migraine product is currently in such retail stores as Walgreens and CVS, and plans to acquire and distribute a disinfectant product through out China, a price of $0.08 would still only equate to a $5 million market cap.





Safe Harbor Statements:

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer
:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated one thousand dollars for research and media alert. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Your use of this website is subject to our terms & conditions. Wall Street Newscast 1998 - 2011

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements
are subject to risks and uncertainties that could cause actual results to differ materially from those projected.